VitaRNA $VITARNA is a blockchain-based project tokenizing intellectual property to fund and govern gene therapy research. More
| Fully Diluted Valuation | $8.82M |
|---|---|
| 24H Trading Volume | $7,200 |
| 24H Low / High | $1.67 / $ 1.77 |
| Circulating Supply | 2.27M |
| Total Supply | 5.00M |
| Max Supply | 5.00M |
| Categories | Ethereum Ecosystem 1 more |
|---|---|
| Founder | Anthony Schwartz |
| Website | vitarna.xyz Whitepaper |
| Socials | |
| Chains | Ethereum Ecosystem |
| Explorer | Ethplorer 2 more |
| Contracts |
0x7b6....5f9c2
|
| Name | Pair | OG Score |
|---|
VitaRNA $VITARNA is a groundbreaking initiative by Artan Bio that combines blockchain technology and gene therapy to address aging-related genetic factors. Centered around the tokenization of intellectual property (IP) as an IP-NFT (Non-Fungible Token), VitaRNA $VITARNA creates a unique framework where the community plays an integral role in funding innovative research, governing IP, and driving decision-making processes.
The project raised over $300,000 through tokenized IP-NFTs, allowing community members to actively participate in research and development (R&D), funding allocation, and governance. By decentralizing the ownership of intellectual property, VitaRNA $VITARNA aims to pave the way for a more inclusive and democratic approach to advancing medical innovation.
Key Features
1. Community-Driven Research Governance
Holders of VitaRNA $VITARNA tokens gain voting power, enabling them to influence the direction of R&D priorities, governance of intellectual property, and allocation of funds. This decentralized model empowers the community to actively contribute to the development of innovative therapeutic solutions.
2. Gene Therapy for Aging
Artan Bio's core focus is on developing gene therapies that target aging-related genetic mutations. The project seeks to design and validate engineered suppressor systems capable of addressing mutations driving aging. Ultimately, this approach aims to create therapeutic candidates to enhance longevity and health.
3. Tokenized IP-NFT Model
VitaRNA $VITARNA leverages blockchain-based IP-NFTs to represent membership in an IP pool containing intellectual property and R&D data. This ensures a transparent, secure, and equitable system for funding cutting-edge research.
4. Crowdsale for Early-Stage Research
The project conducted a fixed-price token sale, raising $300,000 to fund the next phases of development. Community participation in the crowdsale underlines the importance of collective support in advancing genetic research.
Use Cases
Funding Scientific Research
VitaRNA $VITARNA enables the community to pool resources for advancing preclinical and clinical studies, focusing on creating therapies that extend human longevity.
Intellectual Property Governance
Token holders actively partake in decision-making regarding IP management and research prioritization, ensuring a transparent and decentralized process.
Therapeutic Development
By supporting Artan Bio's research, VitaRNA $VITARNA contributes to the creation of innovative gene therapies that address aging-related mutations.
Community Empowerment in Medical Innovation
Through tokenized ownership, VitaRNA $VITARNA democratizes access to high-impact research and makes cutting-edge science accessible to a broader audience.
Founders, Backers, and Partners
Artan Bio: The company behind VitaRNA $VITARNA, led by two experienced entrepreneurs who have successfully advanced drug development platforms into human clinical trials. Artan Bio's expertise focuses on developing innovative gene therapies to combat aging-related genetic factors.
VitaDAO: A key backer and partner, VitaDAO provided initial funding for Artan Bio through a Sponsored Research Agreement (SRA). It played a crucial role in helping tokenize Artan Bio's IP into IP-NFTs and driving community engagement.
Collaborators: The project collaborates with leading Contract Research Organizations (CROs) to screen and validate therapeutic candidates in preclinical studies, ensuring rigorous research and development standards.
Roadmap Highlights
May 2023: Artan Bio submitted its funding application.
July 2023: Funding for Artan Bio’s IP-NFT was approved by $VITA token holders.
January 2024: The decision was made to tokenize Artan Bio's IP-NFT under VitaRNA $VITARNA.
June 2024: $300,000 was raised through the token sale.
October 2024: Progress updates highlighted advancements in preclinical studies, setting the stage for clinical trials and further R&D.
Conclusion
VitaRNA $VITARNA represents a transformative approach to medical research, combining blockchain technology and gene therapy to address aging-related challenges. By giving the community a voice in governance and funding, VitaRNA $VITARNA exemplifies the potential of decentralization in driving impactful solutions for global health challenges. As research progresses, the project is poised to pioneer new opportunities in longevity science and democratize access to cutting-edge therapies.
VitaRNA $VITARNA uniquely combines blockchain technology with gene therapy, using tokenized IP-NFTs to decentralize research funding and governance.
The founders are Anthony Schwartz, Ph.D., an experienced biotech entrepreneur, and the team at Artan Bio.
The project is backed by VitaDAO and collaborates with leading Contract Research Organizations (CROs).
Uniswap V3 (Ethereum)
Join
OGAudit
